Sunday 18 October 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTX
Insiders bought in the last twelve months.
20.08
0.64
−3.09%
Follow SCTX
| Jun '26 | Dec '25 | Jun '25 | |
|---|---|---|---|
P/S ratio |
0.00 | — | 0.00 |
P/FCF ratio |
0.00 | — | 0.00 |
P/Operating CF |
0.00 | — | 0.00 |
P/B ratio |
0.00 | — | 0.00 |
Price to Tangible BV |
0.00 | — | 0.00 |
EV/Sales |
0.00 | — | 0.00 |
EV/EBITDA |
0.00 | — | 0.00 |
EV/Operating CF |
0.00 | — | 0.00 |
EV/FCF |
0.00 | — | 0.00 |
Quick Ratio |
0.56 | 0.94 | — |
Current Ratio |
0.57 | 0.97 | — |
Net Debt/EBITDA |
4.58 | 0.00 | 0.00 |
Debt/Assets |
0.00% | 0.00% | — |
Debt/Equity |
0.00 | 0.00 | — |
Operating CF/Net income |
0.00 | — | 0.00 |
Interest Coverage |
(34.04) | — | (19.44) |
Research and Development Expense of Revenue |
460.01% | — | 283.46% |
Selling, General and Administrative Expense of Revenue |
129.82% | — | 53.92% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | — |
Share Based Compensation of Revenue |
0.00% | — | 0.00% |
Graham Net Nets |
(1.22) | — | (1.22) |
Graham Number |
0.00 | — | 0.00 |
Free Cash Flow Yield |
0.00% | — | 0.00% |
Revenue per Share |
0.77 | — | 2.02 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
17.37 | 0.00 | 0.00 |
Shareholders Equity per Share |
(17.97) | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
(17.97) | 0.00 | 0.00 |
EV/EBIT |
0.00 | — | 0.00 |
Capex to Sales |
0.00 | — | 0.00 |
Price to Operating Income |
0.00 | — | 0.00 |
| Other line items | |||
Working Capital |
(33.59) | (2.12) | — |
Net Current Asset Value |
(57.31) | (34.35) | — |
Columns are period end dates · fundamentals updated 29 Sep 2026